Reinsel Ruth A, Starr Tatiana D, O'Sullivan Barbara, Passik Steven D, Kavey Neil B
National Sleep Research Institute, New York, NY.
Department of Anesthesiology, Stony Brook Medicine, Stony Brook, NY.
J Clin Sleep Med. 2015 Dec 15;11(12):1361-70. doi: 10.5664/jcsm.5264.
Insomnia is a frequent complaint in breast cancer patients during and after treatment. Breast cancer survivors, 1-10 years posttreatment, underwent in-lab polysomnography (PSG) to objectively define the insomnia in those patients with such a complaint.
Twenty-six breast cancer survivors (aged 39-80, mean 54.0 months posttreatment) spent 2 nights in the sleep laboratory. Sleep on Night 2 was scored for sleep stages, sleep onset latency, REM sleep onset latency, wake time, apneas and hypopneas, periodic limb movements and arousals. Subjects were allocated into 2 groups by their scores on the Pittsburgh Sleep Quality Index (PSQI): no/ mild sleep disturbance (PSQI score ≤ 9, n = 15) or moderate/ severe sleep disturbance (PSQI ≥ 10, n = 11).
Standard PSG/EEG parameters failed to differentiate insomniacs from non-insomniacs. The single variable that distinguished the insomnia group was periodic limb movements in sleep (PLMS). PLMS were significantly correlated (r ≅ 0.7, p < 0.02) with subjective report of insomnia on PSQI and insomnia severity index. Log[Number of PLMS] was higher in the moderate/severe insomnia group (p = 0.008). Five of 11 patients in the moderate/severe insomnia group had a PLMS index ≥ 15, compared to only one of 15 patients in the none/mild insomnia group (p = 0.02). Menopausal symptoms and use of caffeine, hypnotics, and antidepressants were unrelated to insomnia severity or PLMS.
PLMS was the sole PSG variable that separated breast cancer survivors with moderate/severe insomnia from those with no/mild sleep disturbance. Further study of the incidence and significance of PLMS in breast cancer survivors with the complaint of insomnia is merited.
失眠是乳腺癌患者在治疗期间及治疗后常见的主诉。对治疗后1至10年的乳腺癌幸存者进行实验室多导睡眠图(PSG)检查,以客观界定有此类主诉患者的失眠情况。
26名乳腺癌幸存者(年龄39 - 80岁,治疗后平均54.0个月)在睡眠实验室度过两个夜晚。对第二晚的睡眠进行睡眠阶段、入睡潜伏期、快速眼动睡眠起始潜伏期、觉醒时间、呼吸暂停和低通气、周期性肢体运动和觉醒的评分。根据匹兹堡睡眠质量指数(PSQI)得分将受试者分为两组:无/轻度睡眠障碍(PSQI得分≤9,n = 15)或中度/重度睡眠障碍(PSQI≥10,n = 11)。
标准PSG/脑电图参数未能区分失眠者与非失眠者。区分失眠组的唯一变量是睡眠中的周期性肢体运动(PLMS)。PLMS与PSQI上的失眠主观报告及失眠严重程度指数显著相关(r≅0.7,p < 0.02)。中度/重度失眠组的Log[PLMS数量]更高(p = 0.008)。中度/重度失眠组的11名患者中有5名PLMS指数≥15,而无/轻度失眠组的15名患者中只有1名(p = 0.02)。更年期症状以及咖啡因、催眠药和抗抑郁药的使用与失眠严重程度或PLMS无关。
PLMS是唯一能将中度/重度失眠的乳腺癌幸存者与无/轻度睡眠障碍者区分开来的PSG变量。值得对有失眠主诉的乳腺癌幸存者中PLMS的发生率及其意义进行进一步研究。